VTGN - VistaGen Therapeutics slumps in after hours trade on underwritten public offering

VistaGen Therapeutics (VTGN) -16.8% AH, commenced an underwritten public offering of units consisting of its common stock, par value $0.001/share and its Series D convertible preferred stock.Terms, actual size have not yet been disclosed.Series D Preferred Stock will be initially convertible into a specified number of shares at any time at the holder's option.Proceeds to be used for research, development and manufacturing and regulatory expenses associated with continuing development of PH94B, PH10, AV-101, and potential drug candidates to expand its CNS pipeline and for general corporate purposes.

For further details see:

VistaGen Therapeutics slumps in after hours trade on underwritten public offering